VTV THERAPEUTICS INC. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 25.82 USD | -0.60% |
|
+1.27% | +124.57% |
| May. 09 | VTv Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| Mar. 14 | VTv Therapeutics Inc. Announces Board Changes | CI |
Presenter SpeechStephen Holcombe (Executives)Good morning. Thanks for working through the weat...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for metabolic and inflammatory diseases. Its products pipeline includes TTP399, TTP273, HPP737 and HPP593. TTP399 is an orally administered, small molecule, liver-selective glucokinase activator (GKA) in development potential oral anti-diabetic for the treatment of type I diabetes. TTP399 completed the SimpliciT-I Study, a Phase II trial in patients with type I diabetes as an add-on to insulin therapy. Its HPP737 is an orally administered, non-central nervous system (CNS) penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases. TTP273 is an orally available, small molecule glucagon-like peptide 1 (GLP-1) receptor agonist, which is focused on treating postprandial hyperglycemia in cystic fibrosis related diabetes (CFRD) patients and cystic fibrosis patients. Its products pipeline also includes Azeliragon and HPP3033.
Calendar
2024-06-11
- Annual General Meeting
| 1st Jan change | Capi. | |
|---|---|---|
| +124.57% | 63.21M | |
| +7.39% | 111B | |
| +11.38% | 106B | |
| -12.64% | 22.24B | |
| +0.44% | 21.25B | |
| -4.18% | 18.97B | |
| -37.85% | 18.52B | |
| -8.57% | 16.81B | |
| +37.41% | 12.54B | |
| -24.07% | 8.09B |
- Stock Market
- Equities
- VTVT Stock
- News vTv Therapeutics Inc.
- Transcript : vTv Therapeutics Inc. - Special Call
